B esides the sarcoplasmic reticulum (SR) Ca 2ϩ -ATPase (SERCA), the sarcolemmal Na ϩ -Ca 2ϩ exchanger (NCX) is the most important Ca 2ϩ transport protein responsible for maintaining the Ca 2ϩ balance of the myocyte. It catalyzes the transport of Ca 2ϩ across the membrane in exchange for Na ϩ in a reversible manner. Its activity is called "forward" when Na ϩ is transported inward and Ca 2ϩ outward and "reversed" when ions are transported in the opposite directions. The driving force of NCX depends on Na ϩ and Ca 2ϩ concentrations at either side of the plasma membrane and on the membrane potential. NCX is electrogenic and carries inward (depolarizing) current in forward mode and outward (repolarizing) current in reversed mode. 1 NCX consists of 9 transmembrane helices and a large cytoplasmic loop. This loop has been shown to contain Ca 2ϩ -and Na ϩ -binding regulatory sites, which are distinct from the transport sites. Thus, Na ϩ and Ca 2ϩ ions are both transport substrates and modulators of activity. At the N-terminal end of the cytoplasmic loop near the membrane-lipid interface, there is a 20-amino acid segment, designated the endogenous XIP region. This region is considered to function as an autoinhibitory domain that plays a central role in NCX regulation. In addition, PIP 2 , protons, ATP, and PKCdependent effects regulate NCX activity. 1-3 More recently, it was shown that the Ca 2ϩ binding protein sorcin exerts stimulatory actions on NCX. 4 Altered expression and activity of the sarcolemmal NCX may play a key role for disturbed contractile function and arrhythmogenesis in hypertrophy and heart failure. It has become clear that disturbed excitation-contraction coupling attributable to altered SR Ca 2ϩ accumulation significantly contributes to heart failure pathophysiology. 3 Three major factors seem to contribute to disturbed SR Ca 2ϩ accumulation in human heart failure: (1) increased leak of Ca 2ϩ through ryanodine receptors, (2) reduced SERCA activity, and (3) increased transsarcolemmal elimination of Ca 2ϩ by NCX. SR Ca 2ϩ accumulation depends on the activity of SERCA relative to transsarcolemmal Ca 2ϩ elimination by NCX. When protein levels of NCX were measured relative to SERCA, it was observed that this ratio was increased by a factor of 3 in endstage failing myocardium, indicating a relative dominance of NCX over SERCA Ca 2ϩ transport. 5 Interestingly, two different phenotypes were identified: (1) endstage failing hearts with a predominant increase in protein levels of NCX, and (2) endstage failing hearts with a predominant decrease in SERCA protein levels. In the former subgroup, diastolic function was preserved because overall cellular capacity to eliminate cytosolic Ca 2ϩ is high. However, systolic function was impaired because Ca 2ϩ is eliminated across the sarcolemmal membrane and therefore SR Ca 2ϩ accumulation is decreased. In the latter group, both SR Ca 2ϩ uptake and global cytosolic Ca 2ϩ elimination are reduced and therefore systolic as well as diastolic function was severely compromised. Enhanced transsarcolemmal relative to SR Ca 2ϩ cycling is most pronounced at high heart rates. 5, 6 As was indicated in clinical and experimental studies, increased forward mode exchange is arrhythmogenic because of delayed afterdepolarizations after inward current generation. 1,3 Furthermore, it was shown that increased expression of NCX increases sensitivity to digitalis and predisposes to free radical induced myocyte dysfunction. 3, 7 From these considerations, modulation of NCX function in heart failure may be a therapeutic option. Stimulation of forward mode NCX activity would reduce cytosolic Ca 2ϩ , impair systolic, and improve diastolic function. Vice versa, stimulation of reversed mode NCX would increase intracellular Ca 2ϩ and contractility with the risk of diastolic impairment. Inhibition of NCX function should have opposite effects. Apparently, the consequence of nonselective stimulation or inhibition of NCX function is quite complex and unpredictable. Several inhibitors of NCX function have been developed 2 : KB-R7943 is a well-characterized inhibitor. Intriguingly, KB-R7943 was suggested to exert a preferential effect on reverse-mode NCX activity. First studies also reported high selectivity of the drug; this was yet questioned by other authors. Synthetic peptides are considered as potent and highly selective NCX inhibitors. The NCX inhibiting peptide (XIP) is derived from the primary sequence of cardiac NCX1, binds at the large cytoplasmic loop, and decreases the V max of NCX activity. However, it does not appear to permeate through the cell membrane, which limits its use for therapeutic interventions in heart failure. In addition, other peptides, such as the cyclic hexapeptide FRCRCFa and its cell-permeant, N-myristylated derivative Myr-FRCRCFa, which are much smaller than XIP, have been reported to effectively inhibit NCX activity. Recently, new compounds with particularly high selectivity for NCX such as SEA0400 were synthesized. 2,8
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Correspondence In this issue of Circulation Research, Hobai et al 9 present an interesting study suggesting that inhibition of NCX may be a therapeutic option in heart failure by normalizing Ca 2ϩ cycling and improving contractile function. They studied isolated myocytes from dog hearts with pacing-induced heart failure using single cell electrophysiology techniques with XIP added directly to the intracellular solution. The canine pacing tachycardia model was previously shown to present with decreased SERCA and increased NCX protein levels. The main findings are that NCX inhibition by XIP increases SR Ca 2ϩ load and Ca 2ϩ transients; an estimated 27% inhibition of NCX induced an 80% increase in the amplitude of the Ca 2ϩ transient in nonfailing myocytes at 0.5 Hz. In failing myocytes with doubling of NCX function, a 27% inhibition of NCX induced a 3.86-fold increase in the Ca 2ϩ transient amplitude. Quite surprisingly, inhibition of NCX was not associated with increased diastolic Ca 2ϩ and rather accelerated relaxation kinetics. The finding of increased SR Ca 2ϩ load with reduced NCX activity is consistent with findings using the opposite approach in a previous study. 10 When protein levels of NCX were increased by adenovirus mediated gene transfer in isolated rabbit myocytes, this resulted in decreased SR Ca 2ϩ content, decreased myocyte shortening, and blunted forced frequency relation, ie, findings similar to those observed in the failing human heart. 5, 6 However, it should be mentioned that in other models and experimental conditions, increased NCX expression and function was shown to upregulate SR Ca 2ϩ levels. In these studies, high Na ϩ levels may have been the main cause promoting reversed mode NCX activity. 11 What are the subcellular mechanisms coupling SR Ca 2ϩ load to NCX function? Most likely, NCX inhibition transiently increases intracellular Ca 2ϩ , which subsequently results in stimulation of SERCA. It has been recognized that with increasing stimulation rates, a marked "frequencydependent acceleration of relaxation" (FDAR) can be found in mammalian ventricular muscle. 12 Apparently, FDAR is linked to the frequency-dependent increases in [Ca 2ϩ ] i and is independent from ␤-adrenergic activation. There are several mechanisms to explain SERCA stimulation by Ca 2ϩ . Involvement of phosphorylation of phospholamban (PLN) by Ca 2ϩ /calmodulin-dependent protein kinase (CaMKII) relieving the inhibitory action of PLN on SERCA has first been suggested. Accordingly, FDAR was abolished after inhibition of CaMKII with KN-62 or KN-93. However, it was also present in PLN knockout mice, implying that PLN is not essential. 12 Interestingly, direct phosphorylation of SERCA by CaMKII resulting in stimulation of the V max of Ca 2ϩ uptake has been described as an alternative pathway. 13 However, there is still controversy and the appropriate target of CaMKII involved in accelerating Ca 2ϩ transport during FDAR is not yet identified unequivocally. After SERCA stimulation, intracellular Ca 2ϩ declines and a new steady state with higher SR Ca 2ϩ levels and higher SR Ca 2ϩ release and uptake develops. Of course, under steady state conditions, NCX Ca 2ϩ elimination matches with L-type Ca 2ϩ current influx.
Although the finding of increased SR load and Ca 2ϩ transients after NCX inhibition is plausible for nonfailing as well as failing myocardium, the finding of improved rate of relaxation may depend on the experimental model. In the failing human heart, diastolic Ca 2ϩ was shown to be increased. 1, 3 Furthermore, in muscle strip preparations from failing human hearts, diastolic function varied considerably between patients. Diastolic function was related to expression levels of SERCA and NCX. It was normal in patients with increased NCX and preserved SERCA levels. In those patients, NCX inhibition may improve function by increasing reduced SR Ca 2ϩ load. In patients with reduced SERCA, diastolic function was impaired. In those patients, NCX inhibition may further deteriorate diastolic performance. 5 This may be most pronounced at high heart rates with reduced time for SR Ca 2ϩ transport. On the same line, intracellular Na ϩ is high in human heart failure. 14 Because increased Na ϩ promotes reversed mode NCX activity, 1,3 the consequences of XIP induced NCX inhibition may critically depend on intracellular Na ϩ .
Another aspect needs to be considered. In heart failure, Ca 2ϩ leak from the SR is increased due to enhanced ryanodine receptor open probability. 15 Because leak as measured by Ca 2ϩ sparks is increased with higher SR Ca 2ϩ load any intervention to increase SR Ca 2ϩ load without reducing the leak decreases efficiency of excitation-contraction coupling with increased energy consumption and arrhythmias as potential side effects. Finally, XIP acts at the intracellular surface of the NCX, which was suggested to be involved in Na ϩ -dependent inactivation of the transporter. This together with the finding that XIP did not inhibit NCX function during caffeine induced Ca 2ϩ release in the study by Hobai et al 9 may suggest that the observed functional changes are specific for XIP and may not be generally transferable to other nonspecific NCX inhibitors.
In summary, because NCX is a complex molecule, the regulation of which is incompletely understood, the effects of NCX modulation on intracellular Ca 2ϩ and contractile function is rather unpredictable and may deeply depend on experimental conditions and models. The study by Hobai et al 9 stimulates to consider inhibitors of NCX for improving excitation-contraction coupling in heart failure. However, more studies are needed to understand the effects of XIP and analogues under different conditions such as high stimulation rates, increased intracellular Na ϩ , increased SR Ca 2ϩ leak, and various SERCA and NCX expression levels.
